Medtronic, Philips ink LungGPS lung cancer treatment dev deal

Medtronic (NYSE:MDT) said today it is partnering with Philips (NYSE:PHG) to develop and commercialize the LungGPS patient management platform designed to aid in the identification and management of patients with lung nodules. The LungGPS platform is designed to improve identification and management of patients with incidental pulmonary nodules, and uses natural language processing to analyze medical report data. The system also uses Philips’ lung cancer screening solution which automates routine administrative tasks and clinical workflows to improve efficiency and patient care, the companies said. “Early identification and prompt, appropriate management of pulmonary nodule patients has been proven to improve clinical outcomes. Developing technological solutions to enable our customers to do this quickly, efficiently and consistently continues to be our focus and we’re excited about the expanded possibilities through our new collaboration with Medtronic. The combination of our collective capabilities in imaging, informatics and image-guided intervention has the ability to make a meaningful, positive impact on patient care, clinical outcomes and survivorship,” Philips oncology solutions head Brent Berthy said in prepared remarks. Both Fridley, Minn.-based Medtronic and Amsterdam-based Philips’ early commercialization efforts will look to provide solutions focused on hospital data, patient management and clinical workflows. “Lung cancer rate...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Respiratory Medtronic royalphilips Source Type: news